Tokyo Tape
Sign in
← Oncolys BioPharma

Annual report

4588.TEDINET S100PNC2
Period2021-01-01 → 2021-12-31
Filed2022-11-17
StandardJapan GAAP
ConsolidatedNo
Data checks13 of 13 passed

Amends S100NSY7. Amended by S100PNM1 (2022-11-17).

Key figures · 78
MetricValuePeriodScopeSource row
Revenue¥642m2021-01-01 → 2021-12-31StandaloneNet sales
Revenue¥314m2020-01-01 → 2020-12-31StandaloneNet sales
Revenue¥1.3bn2019-01-01 → 2019-12-31dStandaloneNet sales (5-year summary)
Revenue¥169m2018-01-01 → 2018-12-31dStandaloneNet sales (5-year summary)
Revenue¥229m2017-01-01 → 2017-12-31dStandaloneNet sales (5-year summary)
Operating income−¥1.5bn2021-01-01 → 2021-12-31StandaloneOperating income
Operating income−¥1.7bn2020-01-01 → 2020-12-31StandaloneOperating income
Ordinary income−¥1.5bn2021-01-01 → 2021-12-31StandaloneOrdinary income
Ordinary income−¥1.7bn2020-01-01 → 2020-12-31StandaloneOrdinary income
Ordinary income−¥539m2019-01-01 → 2019-12-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income−¥1.2bn2018-01-01 → 2018-12-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income−¥1.1bn2017-01-01 → 2017-12-31dStandaloneOrdinary income loss (5-year summary)
Profit before tax−¥1.6bn2021-01-01 → 2021-12-31StandaloneIncome before income taxes
Profit before tax−¥2.1bn2020-01-01 → 2020-12-31StandaloneIncome before income taxes
Net income−¥1.6bn2021-01-01 → 2021-12-31StandaloneProfit loss
Net income−¥2.1bn2020-01-01 → 2020-12-31StandaloneProfit loss
Net income−¥912m2019-01-01 → 2019-12-31dStandaloneNet income loss (5-year summary)
Net income−¥1.2bn2018-01-01 → 2018-12-31dStandaloneNet income loss (5-year summary)
Net income−¥1.1bn2017-01-01 → 2017-12-31dStandaloneNet income loss (5-year summary)
Total assets¥4.3bnat 2021-12-31StandaloneAssets
Total assets¥2.8bnat 2020-12-31StandaloneAssets
Total assets¥4.4bnat 2019-12-31dStandaloneTotal assets (5-year summary)
Total assets¥3.4bnat 2018-12-31dStandaloneTotal assets (5-year summary)
Total assets¥3.5bnat 2017-12-31dStandaloneTotal assets (5-year summary)
Total liabilities¥698mat 2021-12-31StandaloneLiabilities
Total liabilities¥793mat 2020-12-31StandaloneLiabilities
Net assets / equity¥3.6bnat 2021-12-31StandaloneNet assets
Net assets / equity¥2.0bnat 2020-12-31StandaloneNet assets
Net assets / equity¥3.5bnat 2019-12-31dStandaloneNet assets
Net assets / equity¥2.9bnat 2018-12-31dStandaloneNet assets (5-year summary)
Net assets / equity¥2.9bnat 2017-12-31dStandaloneNet assets (5-year summary)
Cash and deposits¥3.5bnat 2021-12-31StandaloneCash and deposits
Cash and deposits¥2.1bnat 2020-12-31StandaloneCash and deposits
Cash & equivalents¥3.2bnat 2021-12-31StandaloneCash and cash equivalents
Cash & equivalents¥1.8bnat 2020-12-31StandaloneCash and cash equivalents
Cash & equivalents¥3.1bnat 2019-12-31dStandaloneCash and cash equivalents
Cash & equivalents¥2.2bnat 2018-12-31dStandaloneCash and cash equivalents (5-year summary)
Cash & equivalents¥1.9bnat 2017-12-31dStandaloneCash and cash equivalents (5-year summary)
Operating cash flow−¥1.7bn2021-01-01 → 2021-12-31StandaloneNet cash provided by used in operating activities
Operating cash flow−¥1.5bn2020-01-01 → 2020-12-31StandaloneNet cash provided by used in operating activities
Operating cash flow−¥238m2019-01-01 → 2019-12-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥1.2bn2018-01-01 → 2018-12-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥1.1bn2017-01-01 → 2017-12-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Investing cash flow−¥942,0002021-01-01 → 2021-12-31StandaloneNet cash provided by used in investment activities
Investing cash flow−¥38m2020-01-01 → 2020-12-31StandaloneNet cash provided by used in investment activities
Investing cash flow−¥4m2019-01-01 → 2019-12-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow¥342m2018-01-01 → 2018-12-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow¥132m2017-01-01 → 2017-12-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Financing cash flow¥3.1bn2021-01-01 → 2021-12-31StandaloneNet cash provided by used in financing activities
Financing cash flow¥242m2020-01-01 → 2020-12-31StandaloneNet cash provided by used in financing activities
Financing cash flow¥1.1bn2019-01-01 → 2019-12-31dStandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow¥1.1bn2018-01-01 → 2018-12-31dStandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow¥1.5bn2017-01-01 → 2017-12-31dStandaloneNet cash provided by used in financing activities (5-year summary)
EPS (basic)¥-95.52021-01-01 → 2021-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-145.582020-01-01 → 2020-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-65.552019-01-01 → 2019-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-104.552018-01-01 → 2018-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-106.232017-01-01 → 2017-12-31dStandaloneBasic earnings loss per share (5-year summary)
Net assets per share¥206.86at 2021-12-31StandaloneNet assets per share (5-year summary)
Net assets per share¥136.43at 2020-12-31StandaloneNet assets per share (5-year summary)
Net assets per share¥240.71at 2019-12-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥216.61at 2018-12-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥263.54at 2017-12-31dStandaloneNet assets per share (5-year summary)
Equity ratio83.6%at 2021-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio71.4%at 2020-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio78.7%at 2019-12-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio84.3%at 2018-12-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio82.9%at 2017-12-31dStandaloneEquity to asset ratio (5-year summary)
Shares issued17,405,200at 2021-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued14,641,900at 2020-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued14,331,300at 2019-12-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued13,346,000at 2018-12-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued11,086,000at 2017-12-31dStandaloneTotal number of issued shares (5-year summary)
Employees33at 2021-12-31StandaloneNumber of employees
Employees32at 2020-12-31StandaloneNumber of employees
Employees27at 2019-12-31dStandaloneNumber of employees
Employees30at 2018-12-31dStandaloneNumber of employees
Employees29at 2017-12-31dStandaloneNumber of employees

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

All source rows · 864
ItemContextValueUnit
Fiscal year cover pageFilingDateInstant
Original text (Japanese)第18期(自　2021年１月１日　至　2021年12月31日)
Company name cover pageFilingDateInstant
Original text (Japanese)オンコリスバイオファーマ株式会社
Company name in english cover pageFilingDateInstantOncolys BioPharma Inc.
Title and name of representative cover pageFilingDateInstant
Original text (Japanese)代表取締役社長　　浦田　泰生
Address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)東京都港区虎ノ門四丁目１番28号
Telephone number address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)03－5472－1578(代表)
Name of contact person address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)取締役　　吉村　圭司
Nearest place of contact cover pageFilingDateInstant
Original text (Japanese)東京都港区虎ノ門四丁目１番28号
Telephone number nearest place of contact cover pageFilingDateInstant
Original text (Japanese)03－5472－1578(代表)
Name of contact person nearest place of contact cover pageFilingDateInstant
Original text (Japanese)取締役　　吉村　圭司
Place for public inspection cover page (text)FilingDateInstantText · Plus
Edinet codeFilingDateInstantE30058
Fund codeFilingDateInstant－
Security codeFilingDateInstant45880
Filer name in japaneseFilingDateInstant
Original text (Japanese)オンコリスバイオファーマ株式会社
Filer name in englishFilingDateInstantOncolys BioPharma Inc.
Fund name in japaneseFilingDateInstant－
Fund name in englishFilingDateInstant－
Cabinet office ordinanceFilingDateInstant
Original text (Japanese)企業内容等の開示に関する内閣府令
Document typeFilingDateInstant
Original text (Japanese)第三号様式
Accounting standardsFilingDateInstantJapan GAAP
Whether consolidated financial statements are preparedFilingDateInstantfalse
Industry code when consolidated financial statements are prepared in accordance with industry specific regulationsFilingDateInstant－
Industry code when financial statements are prepared in accordance with industry specific regulationsFilingDateInstantcte
Current fiscal year start dateFilingDateInstant2021-01-01
Current period end dateFilingDateInstant2021-12-31
Type of current periodFilingDateInstantFY
Current fiscal year end dateFilingDateInstant2021-12-31
Previous fiscal year start dateFilingDateInstant2020-01-01
Comparative period end dateFilingDateInstant2020-12-31
Previous fiscal year end dateFilingDateInstant2020-12-31
Next fiscal year start dateFilingDateInstant－
End date of quarterly or semi annual period of next fiscal yearFilingDateInstant－
Amendment flagFilingDateInstanttrue
Identification of document subject to amendmentFilingDateInstantS100NSY7
Report amendment flagFilingDateInstanttrue
Xbrl amendment flagFilingDateInstantfalse
Business results of reporting company (text)FilingDateInstantText · Plus
Company history (text)FilingDateInstantText · Plus
Description of business (text)FilingDateInstantText · Plus
Overview of affiliated entities (text)FilingDateInstantText · Plus
Information about employees (text)FilingDateInstantText · Plus
Business policy business environment issues to address etc (text)FilingDateInstantText · Plus
Business risks (text)FilingDateInstantText · Plus
Management analysis of financial position operating results and cash flows (text)FilingDateInstantText · Plus
Critical contracts for operation (text)FilingDateInstantText · Plus
Research and development activities (text)FilingDateInstantText · Plus
Overview of capital expenditures etc (text)FilingDateInstantText · Plus
Major facilities (text)FilingDateInstantText · Plus
Planned additions retirements etc of facilities (text)FilingDateInstantText · Plus

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 13 of 13 passed
balance sheet identitynon_consolidated 2020-12-31pass rounding
balance sheet identitynon_consolidated 2021-12-31pass
dei present pass
period resolution pass
statement vs summary · net assetsnon_consolidated 2019-12-31pass
statement vs summary · net assetsnon_consolidated 2020-12-31pass
statement vs summary · net assetsnon_consolidated 2021-12-31pass
statement vs summary · operating cash flownon_consolidated 2020-01-01/2020-12-31pass
statement vs summary · operating cash flownon_consolidated 2021-01-01/2021-12-31pass
statement vs summary · revenuenon_consolidated 2020-01-01/2020-12-31pass
statement vs summary · revenuenon_consolidated 2021-01-01/2021-12-31pass
statement vs summary · total assetsnon_consolidated 2020-12-31pass
statement vs summary · total assetsnon_consolidated 2021-12-31pass